OK-432 |
|
Vaxjo ID |
386 |
|
Vaccine Adjuvant Name |
OK-432 |
|
Alternative Names |
OK-432 is also known as Picibanil. |
|
Adjuvant VO ID |
VO_0005668
|
|
Description |
OK-432 is a streptococcal preparation derived from a strain of Streptococcus pyogenes, treated to enhance its antitumor activity and reduce toxicity. It is used as an adjuvant to promote Th1 immune responses. |
|
Stage of Development |
Licensed |
|
Location Licensed |
Japan |
|
Host Species for Testing |
Human |
|
Components |
OK-432, a streptococcal preparation with antineoplastic activity |
|
Preparation |
OK-432 is prepared by treating a strain of Streptococcus pyogenes with penicillin G and heat to enhance its antitumor properties and reduce toxicity before lyophilization. |
|
Dosage |
The article mentions a dosage of 0.5 KE (Klinische Einheit) for use in immunization protocols. |
|
Function |
The authors investigated the in vivo anti-tumor effect of intratumoral administration of bone marrow-derived dendritic cells (DCs) after chemotherapy using an oral fluoropyrimidine anti-cancer drug TS-1, and followed by immunotherapeutic agent OK-432, in two syngeneic tumor-bearing mouse models. Both in Meth-A fibrosarcoma-bearing BALB/c mice and in SCCVII-bearing C3H/HeN mice, 1 week of oral administration of TS-1 effected partial eradication of established tumors. |
|
Safety |
OK-432 has been shown to have a good safety profile in clinical applications, particularly in cancer treatment, but specific safety data related to its use as an adjuvant for allergic diseases are not detailed in the article. |
| References |
Wu et al., 2018: Wu CJ, Tseng PH, Chan CC, Quon S, Chen LC, Kuo ML. OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma. Journal of immunology research. 2018; 2018; 1697276. [PubMed: 30402504].
|
